HiberCell has described eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and spinocerebellar ataxia.

Saniona has announced its program to develop small molecules targeting Kv7 ion channels to treat epilepsy has made sufficient progress to move into lead optimization.

MagicMed Industries has divulged new prenylated psilocybin derivatives acting as 5-HT2A and/or 5-HT1A receptor modulators reported to be useful for the treatment of psychiatric disorders.

Athira Pharma has presented data on the development and evaluation of novel orally bioavailable, blood-brain-barrier-penetrant small-molecule hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) positive modulators for the potential treatment of cognitive impairment.

Beckley Psytech has synthesized new tryptamine analogues acting as 5-HT2A and/or 5-HT2B and/or 5-HT2C receptor agonists reported to be useful for the treatment of depression.

E-Scape Bio has identified indazoles acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) and/or LRRK2 (G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson's dementia, multiple system atrophy, Lewy body dementia, Parkinson's disease and Alzheimer's disease.

Scripps Research Institute and Vova Ida Therapeutics have divulged novel compounds that may inhibit NAD consumption and/or increase NAD synthesis, reported to be useful for neurodegenerative, degenerative and metabolic disorders, including amyotrophic lateral sclerosis, diabetes, nonalcoholic fatty liver disease (NAFLD), Parkinson's disease and renal, metabolic and retinal diseases, among other disorders.

As the resident innate immune cells of the brain, microglia are emerging as key drivers of neurological diseases, but as yet there is no systematic way of exploring their potential as drug targets.

Pasithea Therapeutics announced positive results from a preclinical proof-of-concept study of PAS-002, the company's DNA tolerizing vaccine construct encoding GlialCAM, a molecule that has been recently identified in the brain's white matter, which is the portion of the brain attacked in multiple sclerosis (MS).

An inhibitor of sodium/glucose cotransporter 2 (SGLT2), luseogliflozin, was found to have protective effect in a model of acute ischemic stroke in research by Kyushu University scientists and their collaborators.